Aldeyra Therapeutics Announces Collaboration With The National Organization For Rare Disorders To Enhance Awareness For Sjogren-Larsson Syndrome Patients

Loading...
Loading...
Aldeyra Therapeutics, Inc.
ALDX
(Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will collaborate with the National Organization for Rare Disorders (NORD), a non-profit organization dedicated to helping people with rare diseases. Through this collaboration, Aldeyra and NORD will work to increase awareness of Sjögren-Larsson Syndrome (SLS) and provide patients with opportunities to connect with each other and to access information about their disease, available resources, and ongoing efforts related to diagnosis and treatment. SLS is an orphan disease characterized by severely dry skin, retinal dysfunction, mental delay, and spasticity. Under the agreement, NORD will develop a multi-phased approach to enhance the ability of the SLS population to communicate and receive optimal care through development of a patient contact registry and other tools, such as social media. This will be conducted through RareLaunch™, NORD's capacity-building and mentor program, through which it works with rare disease patients to develop or evolve disease-specific communities for the purpose of sharing information, accessing resources and learning from medical experts. Commenting on the agreement, Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, said, "NORD has been a leading voice for people suffering from rare disorders for over 30 years, helping to bring attention to patient populations that are often overlooked and have severe, unmet medical needs. This collaboration provides the opportunity to bridge a gap in awareness of Sjögren-Larsson Syndrome and will further our continued efforts to facilitate a more connected patient community and better educate physicians who could have patients with this condition." Dr. Brady continued, "With Aldeyra's lead product candidate, NS2, approaching clinical testing, we believe there is an opportunity for significant advancement in how these patients are treated. We look forward to working with our partners at NORD to better understand patient needs and to providing patients with a greater knowledge of all current and future treatment options." "SLS is a rare disease that has a significant impact on the quality of life of those who are afflicted, as well as their caretakers. We are pleased that Aldeyra is pursuing a viable treatment option for this patient community," commented Peter L. Saltonstall, President and CEO of NORD. "We look forward to working with the Aldeyra team to help create further awareness of this disease and the needs of patients living with it."
Loading...
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...